<DOC>
	<DOCNO>NCT00706082</DOCNO>
	<brief_summary>A two-stage prospective observational cohort study scleroderma patient evaluate screen test incidence pulmonary arterial hypertension pulmonary hypertension</brief_summary>
	<brief_title>Early , Simple Reliable Detection Pulmonary Arterial Hypertension ( PAH ) Systemic Sclerosis ( SSc )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Inclusion criterion Male female Age â‰¥ 18 year Patients definite diagnosis SSc American College Rheumatology ( ACR ) criterion ( 18 ) ; include patient connective tissue disease ( CTD ) , parallel , meet ACR criterion SSc ( 18 ) SSc disease duration &gt; 3 year date onset first nonRaynaud feature Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 60 % predict Exclusion criterion PH confirm RHC enrolment , i.e . mean pulmonary arterial pressure ( mPAP ) &gt; = 25 mmHg rest &gt; = 30 mmHg exercise , independent PCWP ( 11 ) RHC within 12 month enrolment Use therapy consider definite PAH/PH treatment ( 19 ) indication , within 6 week enrolment and/or total 6 week 12 month enrolment : i.e . endothelin receptor antagonist ( ERA ; e.g . bosentan , sitaxsentan , ambrisentan ) , phosphodiesterase type 5 inhibitor ( PDE5 ; e.g . sildenafil , tadalafil , vardenafil ) , prostanoids ( e.g . epoprostenol , treprostinil , iloprost , beraprost ) , experimental PAH/PH drug . Intermittent use PDE5 inhibitor male erectile dysfunction permit Forced vital capacity ( FVC ) &lt; 40 % Renal insufficiency , define estimate glomerular filtration rate ( eGFR ) &lt; 40 ml/min/1.73 m2 ( 20 ) , assess accord local practice Previous evidence previous diagnosis clinically relevant leave heart disease relevant condition , i.e . least one following : Previous ECHO estimate leave ventricular ( LV ) ejection fraction &lt; 50 % , previous history cardiogenic pulmonary edema , increase size left atrium ( &gt; 50 mm ) Known significant diastolic dysfunction associate clinical heart failure PCWP &gt; 15mmHg Known significant coronary disease significant valvular heart disease Evidence inadequately treat blood pressure , define &gt; 160/90 mmHg and/or blood pressure exercise &gt; 220/120 mmHg ( evaluate ) Known hypertrophic cardiomyopathy leave ventricular hypertrophy ( interventricular septum thickness ( IVS ) posterior wall thickness ( PWD ) &gt; 1.2 cm ) Patients refer overt heart failure Known congenital heart defect single ventricle , transposition , Eisenmenger physiology Previous closure systemic pulmonary shunt , heart valve replacement , cardiac transplantation Pregnancy : pregnancy test female childbearing potential mandatory must do enrolment Patients unlikely available annual follow anticipate 3 year study ( e.g . survival estimate , psychological , logistics ; base investigator discretion ) Patients clinically relevant leave heart disease define , diagnose ECHO baseline ( i.e . enrolment ) , include study . Additional exclusion criterion patient enrolment During study , use therapy consider definite PAH/PH treatment ( 19 ) prohibit result discontinuation patient study , unless total treatment duration per year less 6 week . Intermittent use PDE5 inhibitor male erectile dysfunction permit . During study , use therapy consider definite PAH/PH treatment ( 19 ) prohibit within 6 week precede followup visit . Violation rule result discontinuation patient study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>